Boxwood Partners Advises iFranchise Group and Top Fire Media on Strategic Investment from L2 Capital

Leading M&A Advisory Firm Adds to Successful Track Record in the Franchising Sector

JUPITER, FL / ACCESSWIRE / January 17, 2024 / Boxwood Partners – a leading boutique middle-market M&A advisory firm – is pleased to announce iFranchise Group received a significant investment from L2 Capital, a lower middle market private equity firm in Devon, PA and Miami, FL. Boxwood Partners, which has established a solid reputation as a premier advisor for middle market clients in the franchising sector, acted as the exclusive sell-side advisor in the transaction.

Leading the deal for Boxwood Partners was Patrick Galleher, Managing Partner, Brian Alas, Managing Director, Clayton Patton, Vice President, John Atkinson, Associate, and Gio Lagnerini, Analyst. The financial terms of the deal were not disclosed.

iFranchise Group, which includes Top Fire Media ("iFranchise") is the market-leading franchising consultant and digital marketing provider for emerging and established brands.

"The highly strategic partnership between iFranchise Group and L2 Capital will lead to accelerated growth and success," Galleher said. "L2 Capital laser focuses on each company in their portfolio, and their ability to spot growth potential is what sets them apart."

L2 Capital has delivered market leading returns since 2010 by investing in niche lower middle market leading consumer and business services companies. L2 executes a differentiated operations-focused strategy, by targeting founder and entrepreneur-led businesses that are at an inflection point where L2’s breakthrough growth framework and direct operating expertise can quickly accelerate market share gain.

"We have been extremely impressed by the iFranchise and TopFire teams and are thrilled to partner with them. We believe that L2 can leverage iFranchise and TopFire Media’s market leading position as we look to achieve breakthrough growth in the Company’s current offerings as well as adjacencies that we have identified," said Peter Batushansky, Partner at L2 Capital.

Mark Siebert of iFranchise Group noted, "Boxwood’s specialized expertise in franchising definitely contributed to a smooth transaction. We are excited for the next chapter of our growth and greatly appreciate the guidance of the Boxwood team throughout the process."

About Boxwood Partners
Boxwood Partners, LLC is a boutique investment bank based in Jupiter, Florida with offices in Richmond, Virginia. Boxwood Partners combines a unique blend of senior-level transaction advisory, business operating experience, and proven process execution skills to give its clients a distinct advantage in the market. The firm’s extensive relationships within the global capital and buyer communities (including U.S. and international private equity groups, corporations, and lenders) and other important transaction-related service providers such as consultants, attorneys, and accountants, ensure that the firm’s clients receive the attention, service, and results they deserve. Boxwood Partners was recently included in The Axial Advisor 100 List, which identifies, verifies and acknowledges the most highly regarded lower middle market sell-side M&A advisors. For more information about Boxwood Partners, please visit

About iFranchise Group
The iFranchise Group is a leading franchise consulting firm that offers strategic planning, operations training and documentation, franchise marketing and sales tools and training, and other important guidance for emerging and established franchisors. Their consultants have helped thousands of businesses assess their franchise potential. They also help existing franchisors improve franchise sales effectiveness, generate more leads, decrease costs and improve franchisee relationships. Specialties include: Franchise feasibility, helping new franchisors, market research, business planning, financial analysis, operations manuals, training programs, online learning, franchise marketing plans, franchise e-brochure development, website content and development, franchise sales training, franchise sales improvement, franchise marketing improvement, franchisee relations, expert witness services, acquisition due diligence, and conversion of dealers to franchises.

About L2 Capital
L2 Capital Partners L2 Capital is a boutique lower middle market private equity firm that specializes in making controlling investments in a diverse range of family and founder-built companies with demonstrated market leadership and unlocked potential for growth. L2’s impressive track record over the last decade includes top quartile returns for its portfolio of business services and consumer products companies with enterprise values up to $100 million. L2 Capital adds value by partnering closely with company leadership to meet their strategic and financial goals by providing intimate operational support including a breakthrough growth framework in addition to access to resources and technology gained over 40 years of principal investing experience.

Taylor Nortman
[email protected]

SOURCE: Boxwood Partners LLC

View the original press release on

Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation (“Reverse Stock Split”)

ANN ARBOR, MI / ACCESSWIRE / January 17, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today provided a business update and will be hosting a conference call.

Fourth Quarter Financial Highlights

Revenue for the fourth quarter of 2023 is expected to be over $7 million, a new record for the Company, compared to record fourth quarter 2022 revenue of $6.2 million, primarily driven by strong performance across many product lines, highlighted by a record quarter in the Therapeutic Device segment.

Full Year 2023 Financial Highlights

Revenue for 2023 is expected to be over $25 million, an increase of over 32% compared to 2022 revenue of $18.9 million, primarily driven by:

  • Increases in sales of Therapeutic Devices, which grew ~29% over the prior year, primarily driven by an increase in PulseVet® product sales and the inclusion of a full year of Assisi® product sales; and,
  • Increases in Diagnostic sales, which grew ~250% over the prior year, primarily driven by an increase in TRUFORMA® product sales and revenue from the launches of the VetGuardian® and TRUVIEWTM product lines.

Cash, Cash Equivalents, and Available-for-Sale Securities are expected to be just over $100 million at December 31, 2023.

"The fourth quarter capped off a record year for Zomedica. We grew full year revenue by over 32%, due in large part to the continued strength in our Therapeutic Devices segment, further bolstered by early adoption of newly launched products in our Diagnostics segment throughout the year," commented Zomedica Chief Executive Officer, Larry Heaton. "During 2023, we created a tremendous amount of momentum in the business that included multiple acquisitions, new product launches, and the improvement of our manufacturing capabilities. With this foundation in place, and our exciting near-term portfolio expansion plans, we are incredibly well positioned to continue our growth trajectory in 2024.

"Additionally, we continue to evaluate strategic business development and M&A opportunities to further bolster our overall growth opportunity in the large and growing animal health sector. We believe we are well positioned to continue our momentum in 2024 and beyond."

2024 Business Outlook

For the full year 2024, the Company is introducing formal financial guidance, as follows:

  • The Company expects full year revenue in the range of $31 to $35 million, an increase of approximately 40% at the high end of the range, over full year 2023 revenue of over $25 million.

Zomedica believes that growth in 2024 will be driven by the strength of its existing portfolio including recently launched products, supported by investments the Company is making to continue to drive increased adoption and utilization of its products, as well as contributions from a number of new products that the Company expects to launch during 2024. Guidance for 2024 does not incorporate any positive benefits from acquisitions the Company may make during the year.

Seeking Approval for 80 – 1 Reverse Stock Split

As announced on January 10, 2024, the Company will be holding a Special Virtual-Only Meeting of Shareholders ("Special Meeting") on Wednesday, February 28, 2024, at 1:00 p.m. ET, to seek approval to amend the articles of the Company to effect an 80-1 reverse stock split.

The Company believes the reverse stock split will help with a number of initiatives, all of which are aimed at positioning the Company to generate long-term shareholder value. Despite common apprehensions about reverse splits, Zomedica believes its strong operational profile – characterized by rapid growth, solid capitalization, and strong future prospects – differentiates it from typical companies undergoing reverse splits.

Some of the potential benefits from the proposed reverse split include:

  • Attracting a Broader Range of Investors: The reverse split will increase the share price, potentially making Zomedica shares more appealing to institutional investors, investment funds, and brokerage firms, many of which have policies that prevent them from investing in stocks priced below certain thresholds.

Additionally, the 80-1 reverse split brings the share count to a level in line with peers, potentially making it more attractive to equity investors. A higher share price and reduced share count resulting from the reverse split could thus increase institutional investment.

  • Eligibility for Stock Indices Inclusion: With an increased share price, Zomedica could meet the minimum price requirements for inclusion in popular stock indices like the Russell group of indices. Inclusion in such indices often leads to increased demand for shares and facilitates investment by institutional investors who track these indices.
  • Increased Equity Research Analyst Coverage: A higher per share price could also attract more attention from the equity research analyst community, potentially expanding coverage of the company. This expanded coverage could, in turn, introduce the company to a larger pool of individual and institutional investors.
  • Compliance with NYSE Listing Requirements: The reverse split aims to ensure compliance with the New York Stock Exchange’s listing requirements, thus avoiding delisting. Delisting would relegate Zomedica shares to the Over-The-Counter market, where there is typically reduced trading volume and higher risks for investors.

All shareholders of record as of the close of business on Tuesday, January 9, 2024, will be entitled to notice of the Special Meeting, which provides the means to vote. Notice of the Special Meeting will be sent to Shareholders directly from their respective financial institutions and intermediaries.

Shareholders are encouraged to read the Proxy Statement. Additional information regarding the Special Meeting and the reverse stock split, including a Proxy Circular, is available to shareholders and filed on SEDAR+ at and EDGAR at

Details are also available on the Investor Relations tab via the Zomedica Corporate Website: Investor Relations | Zomedica Inc.

Details of the Business Update Conference Call are as follows:

Event: Zomedica Business Update Call

Date: Wednesday, January 17, 2024

Time: 4:30 p.m. Eastern Time

Live Call: 1-877-407-0789 (U.S. Toll Free) or 1-201-689-8562 (International)

Webcast: Zomedica Business Update Webcast

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Wednesday, January 31, 2024, at 11:59 PM ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 13743242.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica’s mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit

Follow Zomedica

Investor Contact:

Zomedica Investor Relations
[email protected]

Cautionary Statement Regarding Forward-Looking Statements – Safe Harbor

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; risk that sales will not meet expectations; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risk associated with our continued listing on the NYSE American; risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

SOURCE: Zomedica Corp.

View the original press release on

Regency Silver Closes First Tranche of Private Placement

VANCOUVER, BC / ACCESSWIRE / January 17, 2024 / Regency Silver Corp. ("Regency Silver" or the "Company") (TSXV:RSMX)(OTCQB:RSMXF) is pleased to announce that it has completed the first tranche of $622,000 of a previously announced non-brokered private placement of $800,000.

Regency Silver has issued 3,110,000 units at a price of $0.20 per unit on this first tranche closing for gross proceeds of CAD$622,000. Each Unit is comprised of one common share of the Company and one half of one transferable common share purchase warrant. Each whole warrant is exercisable to purchase one common share of the Company at a price of CAD$0.30 per share for a period of two years from the date of issuance.

The balance of the private placement is expected to close shortly.

In connection with this closing, the Company paid cash finder’s fees of $6,790 and issued 33,950 broker warrants. Each broker warrant will entitle the holder to purchase one common share of the Company at a price of CAD$0.30 per share for a period of two years from the date of issuance.

All securities issued under the private placement will be subject to a four month hold period from the date of issue in accordance with applicable Canadian securities laws. The private placement remains subject to the final approval of the TSX Venture Exchange.

The proceeds will be used for exploration and development of the Company’s properties and general working capital.

For further details about Regency Silver please visit the Company’s website at

Contact Information

Regency Silver Corp.

Kin Communications Inc.
Phone: 1-604-684-6730
Email: [email protected]

Bruce Bragagnolo, Executive Chairman
Phone: 1-604-417-9517
Email: [email protected]

Gijsbert Groenewegen, Chief Executive Officer
Phone: 1-646-247-1000
Email: [email protected]


Regency Silver Corp. is a Canadian resource company exploring for high grade gold, copper, and silver in Mexico. Regency Silver is led by a team of experienced professionals with expertise in both exploration and production. Regency’s flagship project is the high grade Dios Padre project in Sonora, Mexico where Regency has made a large, high grade, gold-copper-silver discovery which appears to widen at depth. Drill results have included 38 metres of 7.36 g/t gold in hole REG 23-21, 36 metres of 6.84 g/t gold, 0.88% copper and 21.8 g/t silver in hole REG 22-01, and 29.4 m of 6.32 g/t gold in hole REG 23-14.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Regency Silver Corp.

View the original press release on

Aton Announces the Exploitation Lease at the Abu Marawat Concession

VANCOUVER, BC / ACCESSWIRE / January 17, 2024 / Aton Resources Inc. (AAN:TSXV) ("Aton" or the "Company") is pleased to provide investors with an update on its 100% owned Abu Marawat Concession ("Abu Marawat" or the "Concession"), in the Eastern Desert of Egypt.


  • The existence of a Commercial Discovery at the Hamama and Rodruin projects was agreed by the Company and the Egyptian Mineral Resources Authority ("EMRA") on January 17, 2024;
  • The exploitation lease for gold and associated minerals at Abu Marawat was also established and issued on January 17, 2024, in accordance with the procedures and terms of the Abu Marawat Concession Agreement ("CAAM"), and is named the Abu Marawat Exploitation Lease;
  • The exploitation period will be for an initial 20 years, from the date of the establishment of the exploitation lease, and is renewable for a further period of 10 years;
  • The exploitation lease is comprised of 2 separate sectors, with a total area of 57.66 square kilometres, and covers the Company’s main project areas at the Hamama West and Rodruin mineral deposits (Figure 1);
  • The Company will also retain selected areas of the Concession for additional exploration, covering a total area of 255.0 square kilometres, for an additional period of up to 4 years (Figure 1). Other areas within the Concession that are not retained for additional exploration will be relinquished, and the final exploration period of the CAAM has now automatically expired;
  • Aton will rapidly move to establish a Joint Venture company, which will act as the operator of the exploitation lease under the terms of the CAAM, and which will be equally owned by Aton and EMRA;
  • Aton is obligated to commence commercial production of gold from the Concession within 4 years of the date of establishment of the exploitation lease.

"I am very pleased to be able to announce the establishment and issuance of the exploitation lease, or the mining licence, at our Abu Marawat Concession. This is a transformational event for Aton, and also for the mineral exploration and mining sector in Egypt, and we wish to thank our partners at EMRA and also the Ministry of Petroleum and Mineral Resources, under the auspicious leadership of H.E. Eng. Tarek el-Molla for their assistance and cooperation in getting this over the line" said Tonno Vahk, Interim CEO. "The establishment of the mining licence at Abu Marawat, for an initial 20 year period, and renewable for a further 10 years provides Aton with the security of tenure required to proceed with our long-stated plan to develop multiple gold mining operations at Abu Marawat. Aton now becomes the first international company to be issued a licence to mine gold in Egypt since the Sukari mining licence was awarded in 2005. We are also delighted to have retained large areas of our choosing for additional exploration, including our recent Semna drill discovery. Semna continues to look extremely promising, and we plan to start a second phase of diamond drilling there in the very near future, now that the mining licence has been issued and established. We are fully confident in our plan to bring Semna and numerous other exploration projects into the exploitation lease in the coming years, with the assistance of our partners at EMRA. We will certainly be moving ahead at pace now as we look to initially develop the gold oxide cap mineralisation at Hamama West, as per our August 2023 submission to EMRA, which demonstrated the existence of the Commercial Discovery at the Hamama West and Rodruin deposits. We are also planning an aggressive exploration programme on the remainder of our other most prospective targets in the retained exploration areas, with the clear aim of bringing them into the mining licence area as soon as possible, along with Semna. This is truly a landmark event for Aton and for all of its shareholders and stakeholders, as well as for EMRA and the Ministry of Petroleum and Mineral Resources, and most importantly for Egypt, for its people and for the development of its mining industry. All of the team at Aton in both Egypt and Canada are excited to finally now be able to push ahead with the development of the next commercial gold mines in Egypt."

Figure 1: Abu Marawat Concession map, showing the outline of the new exploitation lease and retained exploration areas

About Aton Resources Inc.

Aton Resources Inc. (AAN:TSXV) is focused on its 100% owned Abu Marawat Concession ("Abu Marawat"), located in Egypt’s Arabian-Nubian Shield, approximately 200 km north of Centamin’s world-class Sukari gold mine. Aton has identified numerous gold and base metal exploration targets at Abu Marawat, including the Hamama deposit in the west, the Abu Marawat deposit in the northeast, and the Rodruin deposit in the south of the Concession. Two historic British gold mines are also located on the Concession at Semna and Sir Bakis. Aton has identified several distinct geological trends within Abu Marawat, which display potential for the development of a variety of styles of precious and base metal mineralisation. The Abu Marawat exploitation lease is 57.66 km2 in size, covering the Hamama West and Rodruin mineral deposits, and was established In January 2024 and is valid for an initial period of 20 years. The Concession also includes an additional 255.0 km2 of exploration areas at Abu Marawat, retained for a further period of 4 years from January 2024. Abu Marawat is located in an area of excellent infrastructure; a four-lane highway, a 220kV power line, and a water pipeline are in close proximity, as are the international airports at Hurghada and Luxor.

Qualified person

The technical information contained in this News Release was prepared by Javier Orduña BSc (hons), MSc, MCSM, DIC, MAIG, SEG(M), Exploration Manager of Aton Resources Inc. Mr. Orduña is a qualified person (QP) under National Instrument 43-101 Standards of Disclosure for Mineral Projects.

For further information regarding Aton Resources Inc., please visit us at or contact:

Interim CEO
Tel: +1 604 318 0390
Email: [email protected]

Note Regarding Forward-Looking Statements

Some of the statements contained in this release are forward-looking statements. Since forward-looking statements address future events and conditions; by their very nature they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Aton Resources, Inc.

View the original press release on

SA Formal, a Ladies Formal Fashion Company, Sees A Surge In Positive Reviews After Increasing Investments In Customer Service

LOS ANGELES, CA / ACCESSWIRE / January 17, 2024 / SA Formal, a prominent name in the lady’s formal fashion industry, is celebrating a remarkable surge in positive reviews following its strategic decision to enhance investments in customer service. The brand’s commitment to delivering exceptional experiences has garnered widespread recognition, resulting in a substantial increase in customer satisfaction and loyalty.

With an extensive range of elegant formal wear tailored to meet the needs of modern women, SA Formal has not only caught the eye of fashion enthusiasts but has also captured their hearts through its renewed emphasis on providing a superior shopping journey.

The recent influx of positive reviews serves as a testament to SA Formal’s successful endeavor. One delighted customer shared, "I recently had the pleasure of shopping with SA Formal, and I must say, their dedication to customer service is truly unmatched. The staff went above and beyond to assist me in finding the perfect gown for a special event. Their personalized attention and care made the entire experience unforgettable."

Another review highlighted the brand’s commitment to resolving issues promptly noting that, "Despite a minor sizing issue with my order, I was amazed by how quickly SA Formal’s customer service team addressed the problem. They were incredibly responsive and accommodating, ensuring I received a replacement in time for my event. It’s reassuring to know that they prioritize their customers’ satisfaction."

One customer recounted her exceptional shopping experience saying, "As someone who prefers online shopping, I was pleasantly surprised by SA Formal’s website. The user-friendly interface and detailed product descriptions made selecting the perfect dress a breeze. The timely updates on my order’s status further added to my confidence in the brand."

Another satisfied patron highlighted SA Formal’s dedication to quality noting that, "The dress I purchased from SA Formal is a work of art. The attention to detail and the craftsmanship that went into its creation speaks volumes about the brand’s commitment to excellence. I received numerous compliments at the event, and I couldn’t be happier with my choice."

SA Formal intends to keep investing in making customer services better. While commenting on the growing positive perception, an SA Formal spokesperson said that,

The surge in positive reviews reflects SA Formal’s dedication to redefining the way women shop for formal wear, emphasizing not only stylish designs but also exceptional customer service. Our investments in enhancing the shopping experience have undoubtedly struck a chord with our valued customers. We intend to double down and make our services even better.

SA Formal is a leading lady’s formal fashion brand known for its exquisite range of formal wear designed for the modern woman. With a focus on quality, style, and customer service, SA Formal aims to empower women by offering them elegant and sophisticated attire for various formal occasions.

Learn More:


Email: [email protected]
Phone: +1 (888) 314-4266


View the original press release on

WD Styles, A Formal Menswear Fashion Company, Gets Multiple Positive Reviews For Its Exceptional Customer Service

LOS ANGELES, CA / ACCESSWIRE / January 17, 2024 / WD Styles, a renowned formal menswear fashion company, is earning widespread acclaim as multiple customers share their glowing feedback, highlighting the brand’s unparalleled customer service and dedication to quality. Offering an array of sophisticated formal attire, WD Styles continues to impress not only with its impeccable designs but also with its unwavering commitment to delivering an exceptional shopping experience.

Here are some of the reviews that touch on the value that WD Styles is offering to customers.

★★★★★ Impeccable Quality and Style! One ecstatic customer said about their recent purchase adding that, "The quality of the fabric, the attention to detail in stitching, and the overall fit are outstanding. The suit exudes a timeless elegance that is perfect for formal events. I received numerous compliments and inquiries about where I got it. WD Styles has truly set a high standard for formal menswear."

★★★★☆ Stylish Finds, Slight Sizing Issue. Another satisfied patron shared their thoughts. They also said that, "I adore WD Styles’s collection of formal menswear. The designs strike the right balance between classic and modern. My only gripe was with the sizing – the pants were a bit snug even though I ordered my usual size. Nonetheless, their customer service promptly assisted me in finding a solution. The quality and style are top-notch, and I appreciate their dedication to customer satisfaction."

★★★★★ Exceptional Tailoring and Service Highlighting the brand’s exceptional service, a customer recounted their experience. This one added that, "WD Styles delivers beyond expectations. From the moment I stepped into their store, the staff provided exceptional service, guiding me through various options and helping me find the perfect tuxedo for my wedding. The tailoring was flawless, resulting in a suit that fit like a glove. The compliments I received on my big day were a testament to WD Styles’s craftsmanship and commitment to excellence."

★★★★☆ Great Selection, Slight Delays a loyal patron with years of association with the brand mentioned. This client further reviewed WD Styles stating that, "I have been a loyal customer of WD Styles for several years due to their fantastic selection of formal attire. However, on my recent order, there were slight delays in shipping, which was a bit inconvenient. Nevertheless, the suits I received were as impeccable as ever, showcasing the brand’s signature attention to detail and sophisticated style. I hope they can address the shipping issue to maintain their high standards of service."

★★★★★ Unparalleled Elegance Capturing the essence of WD Styles’s offerings, another delighted customer commented. He added that, "When it comes to formal menswear, WD Styles is unparalleled. Their suits exude elegance and class, making a statement at every formal event I attend. The material is luxurious, and the craftsmanship is evident in every stitch. I appreciate how they cater to various tastes, offering both traditional and contemporary designs. If you want to make a lasting impression, WD Styles is the way to go."

According to a WD Styles spokesperson, the growing positive reviews are a reflection of increased investments in customer service. He noted that,

In the last two years, we have made huge investments both in human resources and systems improvement to ensure that we give our customers the best. We are now able to deliver on orders faster, and also deal with complaints much quicker. We intend to keep improving on our systems and give our customers value for every dollar they spend on us.

WD Styles is a leading online retailer specializing in men’s formal wear. The brand’s keen focus on exceptional quality, craftsmanship, and customer service sets it apart in the industry. With a diverse collection of suits, tuxedos, and formal accessories, WD Styles caters to various preferences and occasions, ensuring every customer finds their perfect fit. To learn more about their products, check out>>>

Email: [email protected]
Phone: +1 800-410-7437


View the original press release on